Colossal Creates Elephant Stem Cells for the First Time in Quest to Revive the Woolly Mammoth – Singularity Hub
By daniellenierenberg
Colossal Creates Elephant Stem Cells for the First Time in Quest to Revive the Woolly Mammoth Singularity Hub
Read the original post:
Colossal Creates Elephant Stem Cells for the First Time in Quest to Revive the Woolly Mammoth - Singularity Hub
Vitamin A could have a key role in both stem cell biology and wound healing: Study – Medical Dialogues
By daniellenierenberg
Vitamin A could have a key role in both stem cell biology and wound healing: Study Medical Dialogues
A dive into the genetic history of India, and the role of vitamin A in skin repair – Science
By daniellenierenberg
A dive into the genetic history of India, and the role of vitamin A in skin repair Science
Continue reading here:
A dive into the genetic history of India, and the role of vitamin A in skin repair - Science
Herbosa: Clinic under probe after skin treatments linked to womans death – Philstar.com
By daniellenierenberg
Herbosa: Clinic under probe after skin treatments linked to womans death Philstar.com
See the article here:
Herbosa: Clinic under probe after skin treatments linked to womans death - Philstar.com
These Will Be the Biggest Skin-Care Trends of 2024 – Allure
By daniellenierenberg
These Will Be the Biggest Skin-Care Trends of 2024 Allure
Original post:
These Will Be the Biggest Skin-Care Trends of 2024 - Allure
Sorry, But These 10 Skincare Products Are A Scam – Refinery29
By daniellenierenberg
Sorry, But These 10 Skincare Products Are A Scam Refinery29
Read this article:
Sorry, But These 10 Skincare Products Are A Scam - Refinery29
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
By daniellenierenberg
- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders
The rest is here:
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
By daniellenierenberg
SAN DIEGO and TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the appointment of Fletcher Payne to Chief Business Officer, in addition to his role as Senior Vice President, Chief Financial Officer.
Go here to read the rest:
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
Opthea to Present at the FLORetina 2023 Congress
By daniellenierenberg
MELBOURNE, Australia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced an oral presentation featuring sozinibercept (OPT-302) which will be presented at the annual FLORetina Congress being held November 30 to December 3, 2023, in Rome, Italy.
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
By daniellenierenberg
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Nov. 30, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:?HCM; HKEX:?13) today highlights that new clinical data from several ongoing studies with HUTCHMED investigational drug candidates fruquintinib, surufatinib and HMPL-295, which will be presented at the upcoming European Society for Medical Oncology (“ESMO”) Asia Congress, taking place on December 1-3, 2023 in Singapore, and the ESMO Immuno-Oncology Congress, taking place on December 6-8, 2023 in Geneva, Switzerland.
See the rest here:
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
Publication of a transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)
By daniellenierenberg
MONT-SAINT-GUIBERT, Belgium, Dec. 01, 2023 (GLOBE NEWSWIRE) -- regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a transparency notification dated November 28, 2023, from Tolefi SA and related persons indicating that they have jointly crossed passively below the 15% threshold, holding 6,568,978 shares, or 14.997 % of the voting rights of the Company as of November 14, 2023.
Go here to see the original:
Publication of a transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
By daniellenierenberg
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
See the article here:
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
Annovis Bio Appoints Andrew Walsh as Vice President Finance
By daniellenierenberg
BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) today announced the appointment of Andrew Walsh as VP, Finance.
Visit link:
Annovis Bio Appoints Andrew Walsh as Vice President Finance
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic…
By daniellenierenberg
CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that clinical data from the Phase 1 dose escalation study of FHD-286 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 9-12, 2023, in San Diego, California.
Read this article:
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic...
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors
By daniellenierenberg
NEW YORK and BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. to the Akari Board of Directors.
Continued here:
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
By daniellenierenberg
NEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that five posters featuring data supporting its OV329 and OV350 programs for the potential treatment of epilepsies and treatment-resistant seizures will be presented at the 2023 American Epilepsy Society (AES) Annual Meeting in Orlando, Florida.
Spectral Medical Announces CFO Departure
By daniellenierenberg
TORONTO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that Blair McInnis has provided notice of his resignation as Chief Financial Officer of the Company, which is effective immediately, to pursue a new opportunity. Mr. McInnis will assist the Company to ensure a smooth transition.
Read the original here:
Spectral Medical Announces CFO Departure
Are STEM CELL EXOSOMES the secret to a ‘snatched’ jawline? Discover the products that influencers are claiming – Daily Mail
By daniellenierenberg
Excerpt from:
Are STEM CELL EXOSOMES the secret to a 'snatched' jawline? Discover the products that influencers are claiming - Daily Mail
Defence Mechanisms: Four ways your body is protecting you every time you fall sick – indulgexpress
By daniellenierenberg
Defence Mechanisms: Four ways your body is protecting you every time you fall sick indulgexpress
See the rest here:
Defence Mechanisms: Four ways your body is protecting you every time you fall sick - indulgexpress
Treat Yourself to a Spa Day With a $100 Deal on $600 Worth of Products From Elemis, 111SKIN, Nest & More – E! NEWS
By daniellenierenberg
Read more from the original source:
Treat Yourself to a Spa Day With a $100 Deal on $600 Worth of Products From Elemis, 111SKIN, Nest & More - E! NEWS